Differentiation therapy: a promising strategy for cancer treatment
Chinese Journal of Cancer volume 35, Article number: 3 (2016)
Poor differentiation is an important hallmark of cancer cells, and differentiation therapy holds great promise for cancer treatment. The restoration of IkB kinase α (IKKα) leads to the differentiation of nasopharyngeal carcinoma cells with reduced tumorigenicity. The findings by Yan et al. validate the polycomb protein enhancer of zeste homologue 2 (EZH2) as a target for intervention.
Traditional chemotherapy or radiotherapy generally involves killing tumor cells [1, 2]. However, cancer cells may instead be coaxed into becoming normal cells by differentiation therapy, which aims to reactivate endogenous differentiation programs in cancer cells to resume the maturation process and eliminate tumor phenotypes (Fig. 1). Generally, differentiation agents tend to have less toxicity than conventional cancer treatments. A prototype differentiation therapy is all-trans-retinoic acid (ATRA), which induces complete remission in patients with acute promyelocytic leukemia (APL). ATRA induces terminal cell differentiation by disrupting the promyelocytic leukemia/retinoic acid receptor α (PML/RARα) fusion protein that arrests the maturation of myeloid cells at the promyelocytic stage . Subsequently, emerging studies have focused on elucidating the mechanisms of action of differentiation therapy in cancers, particularly in solid tumors. In a paper published on Nature Communications, Yan et al.  demonstrated that restoring IkB kinase α (IKKα) expression led to cellular differentiation in nasopharyngeal carcinoma (NPC) (Fig. 2).
NPC is a distinct type of head and neck cancer, and the undifferentiated type (WHO III) is most prevalent (accounting for more than 97% of cases in South China) . The reason for the differentiation block is unclear. This unique characteristic provides an excellent model for exploring the possibility of differentiation therapy in NPC. To identify the key molecules that are essential for NPC cell differentiation, Yan et al.  compared three paired RNA libraries from NPC tumors and adjacent non-tumorous tissues, validated their findings by real-time polymerase chain reaction (PCR) and Western blotting assays, and determined that IKKα down-regulation is involved in the undifferentiated status of NPC. This conclusion was also evidenced by the functional analysis, which showed that restoring IKKα in poorly differentiated NPC cell lines (including CNE2, HONE1, and SUNE1) induced differentiation in vitro and decreased tumorigenicity in vivo. IKKα overexpression led to both morphologic and molecular changes in cells that were comparable to well differentiated NP69 and CNE1 cells . Additionally, Yan et al.  performed colony formation and nude mouse xenograft assays to reveal the significant suppression of cell proliferation and tumor growth in CNE2-IKKα cells. These findings suggest that IKKα plays a crucial role in NPC differentiation. This function of IKKα is consistent with the result reported by previous studies [6–9] that deleting IKKα resulted in a hyperproliferative and undifferentiated epidermis. Moreover, reintroducing IKKα induces terminal differentiation and inhibits hyperproliferation in IKKα−/− keratinocytes. Although there is clear evidence that decreased IKKα expression is associated with high-grade disease and poor differentiation in human squamous cell carcinoma (SCC) [10, 11], the underlying molecular mechanisms for IKKα repression have not been completely elucidated.
Furthermore, through luciferase reporter and chromatin immunoprecipitation (CHIP) assays, Yan et al.  demonstrated that IKKα was epigenetically silenced by an enhancer of zeste homologue 2 (EZH2)-dependent mechanism. Moreover, immunohistochemistry analysis of multiple primary NPC specimens demonstrated that a significant majority of undifferentiated NPC tissues had high EZH2 levels and low IKKα expression, indicating that the phenomenon described for the intensely studied cell line is not isolated.
Importantly, Yan et al.  used a classical differentiation reagent, ATRA, to restore IKKα expression and induce the differentiation of poorly differentiated NPC cells. They used a 3-dimentional (3D) cell culture model and showed that after ATRA treatment, the disordered tumor cell mass reorganized into polarized structures compatible with clinical non-cancerous nasopharyngeal specimens. Certainly, it will be interesting to determine the mechanisms by which ATRA reduces the expression of EZH2 and abrogates EZH2-mediated epigenetic repression.
The significance of the study  lies not only in its elucidation of IKKα function in NPC differentiation but also in the demonstration of the mechanism for IKKα repression in NPC. Recently, another interesting study reported that restoring the function of the tumor suppressor the adenomatous polyposis coli (APC) causes complete tumor regression with normal differentiation and reestablishes stem cell function in mouse intestinal tumors induced by APC inhibition . Together, these findings enhance our confidence in differentiation therapy and its high translational value in the clinic.
However, many challenges remain for cancer differentiation therapy, particularly in solid tumors. First, the molecular mechanisms responsible for differentiation blocks may vary among different tumor types and patients, even for tumors of equivalent histological class and grade. Second, for the most part, cancer cells cannot completely revert to normal cells with relevant functionality. Third, although many reagents have demonstrated the ability to induce differentiation in preclinical models, few such reagents can be applied in the clinic.
There is evidence that epigenetic regulation plays a crucial role in cell differentiation and embryonic development, as well as in the self-renewal of cancer stem cells [13–15]. Based on the structural and mechanistic complexity of solid tumor differentiation, which is generally regulated by a group of genes, exploring the molecular mechanisms of epigenetic networks may provide new insights for the treatment of solid tumors with differentiation therapy.
Della Pepa C, Tonini G, Pisano C, Di Napoli M, Cecere SC, Tambaro R, et al. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer. 2015;34(1):17–27.
Dhermain F. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches. Chin J Cancer. 2014;33(1):16–24.
Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324(20):1385–93.
Yan M, Zhang Y, He B, Xiang J, Wang ZF, Zheng FM, et al. IKKalpha restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat Commun. 2014;5:3661.
Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5(5):423–8.
Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature. 2001;410(6829):710–4.
Liu B, Xia X, Zhu F, Park E, Carbajal S, Kiguchi K, et al. IKKalpha is required to maintain skin homeostasis and prevent skin cancer. Cancer Cell. 2008;14(3):212–25.
Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, et al. Limb and skin abnormalities in mice lacking IKKalpha. Science. 1999;284(5412):313–6.
Sil AK, Maeda S, Sano Y, Roop DR, Karin M. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature. 2004;428(6983):660–4.
Xiao Z, Jiang Q, Willette-Brown J, Xi S, Zhu F, Burkett S, et al. The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas. Cancer Cell. 2013;23(4):527–40.
Liu B, Park E, Zhu F, Bustos T, Liu J, Shen J, et al. A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci USA. 2006;103(46):17202–7.
Dow LE, O’Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, et al. APC restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell. 2015;161(7):1539–52.
Meshorer E, Misteli T. Chromatin in pluripotent embryonic stem cells and differentiation. Nat Rev Mol Cell Biol. 2006;7(7):540–6.
Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 2002;3(9):662–73.
Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39(2):157–8.
MY wrote the manuscript and drafted the figures. QL conceived the manuscript, and helped to write the manuscript. Both authors read and approved the final manuscript.
This work was supported by the National Basic Research Program of China (973 Program, No. 2012CB967000 and 2011CB504300 to QL), Program for Chang Jiang Scholars and Innovative Research Team in University (IRTI 3049 to QL), National Natural Science Foundation of China (No. 30888003 to QL and No. 81201547 to MY), and Guangdong Medical Science Fund (A2011198 to MY).
All authors declare that they have no competing interests.
About this article
Cite this article
Yan, M., Liu, Q. Differentiation therapy: a promising strategy for cancer treatment. Chin J Cancer 35, 3 (2016). https://doi.org/10.1186/s40880-015-0059-x